Characterizing Lithium-Mediated Nucleoside Transport by Human Concentrative Nucleoside Transporters 1 and 3 (hCNT1 and hCNT3)
DOI:
https://doi.org/10.29173/eureka28774Keywords:
electrophysiology, nucleoside transport, Xenopus laevis, two-electrode voltage clamp, secondary active transporters, influx ratesAbstract
The human concentrative nucleoside transporters (hCNTs) utilize coupling and movement of cations down their electrochemical gradient to mediate inward transport of nucleosides against their concentration gradient. Of the three hCNT family members, hCNT3 exhibits the broadest nucleoside selectivity and cation specificity, utilizing Na+, Li+, and H+ to drive nucleoside transport. Xenopus laevis oocytes were injected with hCNT1 and hCNT3 RNA transcripts and incubated for 48 hours to allow protein expression and localization to the plasma membrane. The two-electrode voltage clamp (TEVC) method was used to perform electrophysiological studies. Oocytes were voltage-clamped, and currents were measured in response to various cation conditions, addition of different nucleosides and changes in membrane potential. Voltage-dependence of hCNT1- and hCNT3-mediated uridine uptake and hCNT3-mediated nucleoside uptake-induced currents was determined using NaCl, ChCl and LiCl transport media. Li+ addition resulted in decreases in uptake of uridine both by hCNT1 and hCNT3. hCNT1 and hCNT3 exhibited similar trends in voltage-dependence of uridine transport; currents generated increased as potentials became more negative. It was shown that whereas Na+-coupled hCNT3 has broad nucleoside selectivity, Li+-coupled transport varied widely and was greatest for uridine, and least for thymidine (uridine > cytidine > guanosine > adenosine > inosine > thymidine). Our results indicate a possible role of the nucleoside nitrogenous base ring structure in the differential uptake of various nucleosides. Despite no significant role of Li+ in vivo, further understanding of hCNT3 interactions with this cation may lead to a better understanding it’s transport mechanism and assist in the future design and delivery of effective anti-cancer drugs and anti-viral nucleoside drugs.
Keywords: electrophysiology, nucleoside transport, Xenopus laevis, two-electrode voltage clamp, secondary active transporters, influx ratesDownloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Eureka
This work is licensed under a Creative Commons Attribution 4.0 International License.
By signing the Eureka publication agreement, authors agree to the following:
- The work has not been previously published in any format;
- Eureka is granted the royalty-free right to publish and disseminate the work in current and future formats;
- The work will be published in Eureka under a Creative Commons license. Eureka encourages authors to publish the work under a Creative Commons Attribution 4.0 International license (CC BY 4.0) that allows others to distribute, tweak, and build upon the work, even commercially, as long as they credit the Author(s) for the original creation.
Authors may however choose to have their work distributed under any of the Creative Commons licenses currently available by specifying their preferred license in the publication agreement. A description of the Creative Commons licenses is available here: https://creativecommons.org/licenses/
- Authors retain their copyright, including the right to subsequently publish or disseminate their work elsewhere, provided that they make reasonable efforts to ensure that the publication in Eureka is acknowledged.
- Authors agree to determine, prior to publication, whether it is necessary to obtain permissions from any third party who hold rights with respect to any photographs, illustrations, drawings, text, or any other material (“third party work”) to be published in connection with your work. Copyright permission will not be necessary if the use is determined to be fair dealing, if the work is in the public domain, or if the rights-holder has granted a Creative Commons or similar license.
- All co-authors and investigators (e.g. faculty supervisors) with claims to the intellectual property have read and signed the agreement, thereby providing their consent for the submission to be published in Eureka.
Unless otherwise specified, authors guarantee that all parts of the submission are the author’s original work. Submissions containing evidence of plagiarism will not be eligible for publication.